Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advisory Panel Backs Approval Of Auxilium's Xiaflex, Wants Post-Market Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Members agree 12-0 that drug is approvable, offer opinion on who should dispense and the amount of training needed.

You may also be interested in...



Financings Of The Fortnight: IPOs Make A Return In Talecris And Omeros Deals

Money continued to flow to big and small biotechs, including nearly a dozen PIPEs or registered direct offerings.

Financings Of The Fortnight: IPOs Make A Return In Talecris And Omeros Deals

Money continued to flow to big and small biotechs, including nearly a dozen PIPEs or registered direct offerings.

Auxilium Xiaflex's Advisory Committee To Focus On Physician Expertise, Training

Majority of clinical trial investigators were hand or orthopedic surgeons and FDA asks if this level of expertise is needed to safely use the biologic.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel